Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Wedbush

Wedbush initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Friday. The brokerage issued an outperform rating and a $11.00 price objective on the stock.

A number of other brokerages have also commented on VYGR. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners assumed coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price for the company. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $17.50.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $6.86 on Friday. The stock has a 50 day moving average price of $6.50 and a 200 day moving average price of $7.32. Voyager Therapeutics has a 52-week low of $5.19 and a 52-week high of $11.72. The firm has a market capitalization of $374.76 million, a P/E ratio of 9.44 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period last year, the company earned ($0.59) earnings per share. As a group, sell-side analysts forecast that Voyager Therapeutics will post -1.03 EPS for the current year.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This trade represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its position in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics in the second quarter worth $85,000. Intech Investment Management LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter worth $74,000. Victory Capital Management Inc. grew its holdings in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $128,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.